Deal Library / Pharma BD Deal Intelligence

Pharma Deals of 2004

The Pharma Closeout tracks 17 deals, $86.6B in disclosed deal value, 15 with a post-close Outcome Score for the year 2004.

Median Critic Score: 75  ·  Median Outcome Score: 46

Best outcome: UCB SA / Celltech Group plc (92)  ·  Weakest outcome: Inflazyme Pharmaceuticals Ltd. / AdProTech Limited (8)

All 17 deals

• UCB SA / Celltech Group plc — 2004 · $2.7B · Worked — the deal delivered on its rationale.
• Yamanouchi Pharmaceutical Co. Ltd. / Fujisawa Pharmaceutical Co. Ltd. — 2004 · $7.6B · Worked — the deal delivered on its rationale.
• Abbott Laboratories / TheraSense Inc. — 2004 · $1.2B · Worked — the deal delivered on its rationale.
• Sanofi-Synthelabo SA / Aventis SA — 2004 · $65.0B · Worked — the deal delivered on its rationale.
• Genzyme Corporation / ILEX Oncology Inc. — 2004 · $1.0B · Largely worked — most objectives met.
• Hospira Inc. / Abbott Hospital Products Division — 2004 · Mixed — partial payoff, real shortfalls.
• Boehringer Ingelheim / Boehringer Ingelheim Shionogi Vetmedica (Shionogi stake) — 2004 · Mixed — partial payoff, real shortfalls.
• Cephalon Inc. / CIMA Labs Inc. — 2004 · $515M · Mixed — partial payoff, real shortfalls.
• Novartis AG / Sabex Holdings Ltd. — 2004 · $565M · Underwhelmed — fell short of the thesis.
• Merck & Co. Inc. / Aton Pharma Inc. — 2004 · Underwhelmed — fell short of the thesis.
• Amgen Inc. / Tularik Inc. — 2004 · $1.3B · Underwhelmed — fell short of the thesis.
• Inverness Medical Innovations Inc. / Ischemia Technologies Inc. — 2004 · $22M · Underwhelmed — fell short of the thesis.
• Pfizer Inc. / Vicuron Pharmaceuticals Inc. — 2004 · $1.9B · Did not work — the deal failed to deliver.
• Boston Scientific Corporation / Advanced Bionics Corporation — 2004 · $740M · Did not work — the deal failed to deliver.
• Inflazyme Pharmaceuticals Ltd. / AdProTech Limited — 2004 · $20M · Did not work — the deal failed to deliver.
• Inverness Medical Innovations Inc. / Binax Inc. — 2004
• Mylan Laboratories Inc. / King Pharmaceuticals Inc. — 2004 · $4.0B

← Deal Library  ·  Interactive search  ·  How we score deals